FDA approves oral combination treatment for patients with myelodysplastic syndromes

The U.S. Food and Drug Administration has approved the oral combination of decitabine and cedazuridine (INQOVI, Astex Pharmaceuticals, Inc) for the treatment of adults with myelodysplastic syndrome.

Treatment is intended for patients with previously treated and untreated, de novo, and secondary MDS with the following French-American-British subtypes of refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia and for intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.

Read the full press release here.